Dyne Upsizes Offering to $375M at $20.50, a 4% Discount to Market
DYN has more than doubled off its 52-week low of $8.88.
Summary
Dyne Therapeutics priced an upsized public offering of 18.3 million shares at $20.50 per share, raising $375 million — a 25% increase from the $300 million deal filed just yesterday. The price represents a 4% discount to the last close of $21.30, signaling strong demand despite the dilutive impact. The offering is expected to close on or about July 23. This follows the recent FDA acceptance of its BLA for z-rostudirsen with Priority Review, a key catalyst that likely enabled the raise. The offering funds the neuromuscular pipeline, but the quick upsizing and discount suggest the company is capitalizing on the regulatory momentum while shares are elevated. With authorized shares recently doubled to 400 million, dilution is manageable but notable.
At the time of this announcement, DYN was trading at $21.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $8.88 to $25.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.